Lupin launches generic dapagliflozin and metformin tablets in the US after FDA approval

Published on 24 April 2026

Bioequivalent to Xigduo XR with FDA nod

Lupin has launched generic anti-diabetic tablets in the United States—dapagliflozin and metformin hydrochloride extended-release—after receiving FDA approval. The company says its product is bioequivalent to Xigduo XR, positioning the launch as a potential new option for diabetes patients seeking effective treatment in the US market.

Lupin launches generic dapagliflozin and metformin extended-release tablets in the US
FDA approval has cleared the drug for US launch
The product is bioequivalent to Xigduo XR
The move expands treatment options for US diabetes patients

#diabetes #lupin #generic drugs #fda #dapagliflozin

Read the full story at The Economic Times

This summarization was done by Beige for a story published on The Economic Times

Lupin launches generic dapagliflozin and metformin tablets in the US after FDA approval

The full experience is on mobile.